Pirarubicin-THP-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
Pirarubicin-THP-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
Pirarubicin-THP-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
Pirarubicin-THP-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPirarubicinCat.No.:HY-13725CASNo.:72496-41-4Synonyms:THP分?式:C??H??NO??分?量:627.64作?靶點(diǎn):Topoisomerase;Autophagy;Bacterial;Antibiotic作?通路:CellCycle/DNADamage;Autophagy;Anti-infection儲(chǔ)存?式:4°C,protectfromlight*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)?現(xiàn)配,即刻使?。溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:10mg/mL(15.93mM;ultrasonicandwarmingandheatto80°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.5933mL7.9664mL15.9327mL5mM0.3187mL1.5933mL3.1865mL10mM0.1593mL0.7966mL1.5933mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液;該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)?現(xiàn)配,即刻使?.BIOLOGICALACTIVITY?物活性Pirarubicin(THP)?種蒽環(huán)類抗?素,為拓?fù)洚悩?gòu)酶II(topoisomeraseII)的抑制劑,可?于各種癌癥尤其是實(shí)體瘤的研究。IC50&TargetTopoisomeraseII體外研究PirarubicinisatopoisomeraseIIinhibitor[1].PirarubicinshowsinhibitoryactivitiesagainstM5076andEhrlichcells,withIC50sof0.366and0.078μM,respectively.ThecytotoxicityofPirarubicintowardM5076cellsis1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemElowerthantowardEhrlichcells,andthisisduetothemuchlowerexpressionoftopoisomeraseIIinM5076cellsthaninEhrlichcells[2].Pirarubicin(2.5,5,10μg/mL)significantlyinducesautophagyinadosedependentmannerinbladdercancer(T24,EJ,5637,J82andUM-UC-3)cells.Furthmore,Pirarubicin(5μg/mL)inducesapoptosisthroughinhibitionofmTOR/p70S6K/4E-BP1inbladdercancercells,andthiseffectisenhancedbyinhibitionofautophagy[3].體內(nèi)研究Pirarubicin(18mg/kg,i.v.)significantlyelevatesserumlevelofBNP,CK-MB,CTnT,LDH,andMDAcomparedwiththoseinthecontrolgroupinacutecardiactoxicityrats.Pirarubicinalsolowersheartrate,anddepressesR-wavevoltage,andprolongationofQTintervalsintheacutecardiactoxicitymodel[4].PROTOCOLCellAssay[3]MTSisusedtoanalyzecellsurvival.Briefly,cellsareplatedin96-wellplatesintriplicateat2×103cellsperwellandculturedingrowthmedium.Thencellsaretreatedwithpirarubicinatdifferentconcentrations(2.5μg/mL,5μg/mL,10μg/mL)for24h.MTSreagent(5mg/mL)isaddedandincubatedat37°Cfor4h.Theabsorbanceismonitoredat490nmusingamicroplatereader[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalAnacutecardiactoxicitymodelisestablishedbyasingledoseof18mg/kgpirarubicinthroughthecaudalAdministration[4]veininjection.Thirty-sixratsarerandomizedequallytosixgroups:normalcontrol,cardiacinjury(THP)model,dexrazoxane(180mg/kg),low-doserutin(25mg/kg),middle-doserutin(50mg/kg),andhigh-doserutin(100mg/kg).Ratsintherutin-treatedgroupareadministereddifferentdosesofrutinandCMC-Nafor7daysbygavageandasingledoseof18mg/kgpirarubicinthroughcaudalveininjection.Ratsinthedexrazoxane-treatedgroupreceivesodiumcarboxymethylcellulose(CMC-Na)bygavageforsixdays.40mg/kgdexrazoxaneisthenadministeredtoratsbyintraperitonealinjectionand18mg/kgpirarubicinisadministeredbycaudalveininjectiononday7.RatsintheTHPmodelgroupreceiveCMC-Nabygavageforsevendays,followedbypirarubicin18mg/kgthroughthecaudalveininjectiononday7.RatsinthenormalcontrolgroupreceiveCMC-Nabygavageforsevendays,followedbysalinethroughcaudalveininjectiononday7[4].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?JMolLiq.2020,114633.?IntJPharm.2022May25;620:121761.?JMolMed(Berl).2019Aug;97(8):1183-1193.?Genomics.2021Nov26;S0888-7543(21)00410-9.?Heliyon.June2022,e09643.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[1].TakigawaN,etal.CytotoxiceffectoftopoisomeraseIIinhibitorsagainstadriamycin-andetoposide-resistantsmallcelllungcancersublines.GanToKagakuRyoho.1993May;20(7):929-35.[2].NagaiK,etal.RelationshipsbetweentheinvitrocytotoxicityandtransportcharacteristicsofpirarubicinanddoxorubicininM5076ovariansarcomacells,andcomparisonwiththoseinEhrlichascitescarcinomacells.CancerChemotherPharmacol.2002Mar;49(3):244-50.Epub2002Jan8.[3].LiK,etal.Pirarubicininducesanautophagiccytoprotectiveresponsethroughsuppressionofthemammaliantargetofrapamycinsignalingpathwayinhumanbladdercancercells.BiochemBiophysResCommun.2015May1;460(2):380-5.[4].WangYD,etal.Cardioprotectiveeffectsofrutininratsexposedtopirarubicintoxicity.JAsianNatProd

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論